The exercise price for the warrants of series TO3 in Biosergen AB has been determined to SEK 0.49

Biosergen AB (”Biosergen” or the "Company") completed a rights issue during the first quarter of 2024, consisting of shares and warrants of series TO3. The exercise price for the warrants of series TO3 corresponds to 70 percent of the volume-weighted average price in the Company’s share on Nasdaq First North Growth Market during the measurement period, which ran from and including November 4, 2024, up to and including November 15, 2024, however not higher than SEK 0.50 and not less than SEK 0.30. During the measurement period, the volume-weighted average price in the Company’s share was approximately SEK 0.696, therefore, the exercise price for the warrants of series TO3 is SEK 0.49 per share. One (1) warrant of series TO3 entitles the owner to subscribe for one (1) new share in the Company. The exercise period for warrants of series TO3 runs during the period from and including November 18, 2024, up to and including November 29, 2024.

If all the warrants of series TO3 are exercised, the Company will receive approximately SEK 44.9 million before issuing costs. For the warrants to not expire without value, it is required that the holder actively subscribes for new shares no later than November 29, 2024, or sell the warrants no later than November 26, 2024. Please observe that certain nominees might close their application earlier than November 29, 2024.

Complete terms and conditions for the warrants are available at the Company’s website, www.biosergen.net.

Summarized terms for the warrants of series TO3:
Exercise period: November 18 – November29 024.

Issue size: 91,701,328 warrants series TO3, which entitle to subscription of 91,701,328 shares.

Exercise price: SEK 0.49 per share.

Last day for trading warrants of series TO3: November 26, 2024.

Share capital and dilution: If all warrants are exercised the share capital will increase with approximately SEK 2,292,533.200, from approximately SEK 3,559,679.775 to approximately SEK 5,852,212.975. If all warrants are exercised the number of shares in the Company will increase with 91,701,328 shares, from 142,387,191 shares to 234,088,519 shares. If all warrants of series TO3 are exercised, the dilution will amount to approximately 39.2 percent of the number of shares in the Company.

Please note that warrants that are not exercised no later than November 29, 2024, or sold no later than November 26, 2024, will expire without value. For warrants not to lose their value, the holder must actively subscribe for new shares or sell the warrants.

How warrants are exercised:

Nominee-registered warrants (Custody account)
Subscription and payment by exercise of warrants shall be made in accordance with instructions from each nominee. Please contact your nominee for additional information.

Direct-registered warrants (Securities account)
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form.

The warrants will then be replaced by interim shares awaiting registration at the Swedish Companies Registration Office.The application form

including instructions for payment is available on Biosergen´s website, www.biosergen.net.

Advisers
Mangold Fondkommission AB is the financial advisor and the issuing agent to Biosergen AB in connection with the exercise of series TO3 warrants. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the exercise of series TO3 warrants.

For further information about Biosergen, please contact:
Tine Olesen, CEO
Telephone: +45 3135 5707
E-mail: tine.olesen@biosergen.net

Niels Laursen, CFO
Telephone: +45 4014 5059
E-mail: niels.laursen@biosergen.net

The Company’s Certified Adviser is Carnegie Investment Bank AB (publ).

About Biosergen
Biosergen is a biotechnology company in the clinical stage within the therapeutic field of life-threatening fungal diseases. Biosergen’ s mission is to develop the drug candidate BSG005, into a new first line treatment choice for resistant and/or difficult to treat invasive fungal infections, to save thousands of lives of immune-compromised cancer- transplant- and AIDS patients every year.